In conclusion, we show that combination immunotherapy using OX40 agonism, TIM3 inhibition and Poly(I:C) injected intratumorally into A20 lymphoma tumors leads to complete tumor regression and improved long-term survival. This evidence concerns the gene HAVCR2 and lymphoma.